Abstract
Objective
The rate of suicidal poisoning in the United States has increased substantially over the past 20 years. Understanding whether prescription medications used for self-poisoning were recently dispensed would help inform suicide prevention efforts. Alternatively, medications for self-poisoning could have been formerly dispensed or collected from friends, family, or illicit sources.
Methods
Among those who died by intentional opioid and psychotropic poisonings, we conducted a descriptive study to determine what proportion had a recently filled prescription that could have been the means of suicide. Subjects were all people who died by intentional poisoning across nine health-care systems within the NIH-funded Mental Health Research Network.
Results
Among the 3,300 people who died by suicide, 700 died by any poisoning and 194 died by intentional opioid or psychotropic/hypnotic medication poisoning. Among those who died by intentional opioid poisoning 73% were dispensed an opioid in the year prior. Among those who died by intentional psychotropic/hypnotic poisoning, 83% were dispensed any psychotropic and 61% were dispensed a hypnotic in prior year. Most people were continuously dispensed the same medications used in their intentional poisonings in the year prior to death.
Conclusions
Our results indicate that most medications used in suicidal overdose were likely recently dispensed. Therefore, future suicide prevention studies and prevention resources should focus on medication safety interventions such as lethal-means counseling for medication access, limiting quantities dispensed, opioid antagonists, and blister packs.
Understanding whether medications used for self-poisoning were recently dispensed or formerly/never dispensed would help inform future studies and suicide prevention efforts.
We found that most people who died by intentional poisoning with opioids or psychotropic/hypnotic medications received frequent dispensings of the medication used for self-poisoning in the year prior to death.
Future suicide prevention studies and efforts should focus on medication safety interventions such as lethal-means counseling for medication access, limiting quantities dispensed, opioid antagonists, and blister packs.
HIGHLIGHTS
DISCLOSURE STATEMENT
No potential conflict of interest was reported by the author(s).
AUTHOR NOTES
Jennifer M. Boggs, Institute for Health Research, Kaiser Permanente Colorado Institute for Health Research, Denver, CO, USA. Gregory E. Simon, Kaiser Permanente Washington Research Institute, Seattle, WA, USA. Arne Beck, Institute for Health Research, Kaiser Permanente Colorado Institute for Health Research, Denver, CO, USA. Rebecca C. Rossom, HealthPartners Institute, Bloomington, MN, USA. Frances L. Lynch, Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA. Christine Y. Lu, Department of Population Medicine, Harvard Medical School, and Harvard Pilgrim Health Care Institute, Boston, MA, USA. Ashli A. Owen-Smith, School of Public Health, Georgia State University, Atlanta, GA, USA; Center for Research and Evaluation, Kaiser Permanente Georgia, Atlanta, GA, USA. Stephen C. Waring, Essentia Institute of Rural Health, Duluth, MN, USA. Brian K. Ahmedani, Center for Health Policy and Health Services Research, Henry Ford Health, Detroit, MI, USA; Behavioral Health Services, Henry Ford Health, Detroit, MI, USA. Correspondence concerning this article should be addressed to Jennifer M. Boggs, Institute for Health Research, Kaiser Permanente Colorado Institute for Health Research, Denver, CO, USA. Email: [email protected]